You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a Molecular Diagnostic to Identify Dangerous Intracranial Aneurysms
SBC: NEUROVASCULAR DIAGNOSTICS, INC. Topic: 103Project SummaryIntracranial aneurysm (IA) rupture is the primary cause of non-traumatic subarachnoid hemorrhage, a catastrophic event that carries high rates of mortality (rt50%) and permanent disability (rt50% among survivors). When an unruptured IA is discovered, clinicians face the difficult decision of whether or not it should be treated. Since rupture rates are low (risk of rupture ~ 0.5-1% p ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development and clinical assessment of a robust, 3D printed titanium, myoelectric powered prosthetic digit system
SBC: POINT DESIGNS, LLC Topic: 106ABSTRACT Approximately 600,000 people live with partial hand amputations in the United States, with an estimated 14,500 new cases occurring each year. Despite the advances in miniaturized electronics and motors, there has been very little advancement in mechatronic prosthetic digits for this underserved patient population. In fact, to date, there is only one myoelectric prosthetic option for patie ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Boron-containing antimalarial drug discovery
SBC: REACTIVE BIOSCIENCES INC Topic: NIAIDPROJECT SUMMARY New drugs to treat malaria, ideally with unique chemical structures and mechanisms of action, are urgently needed. Optimal drug candidates for the treatment and prevention of malaria will have potent activity against cultured parasites and in animal models of malaria, be rapidly active against erythrocytic malaria parasites, be orally bioavailable, have extended pharmacological exp ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Neuro-exergaming for the Prevention and Remediation of Decline due to Parkinson's Disease: Clinical Trial of the Interactive Physical and Cognitive Exercise System (iPACES v3)
SBC: iPACES LLC Topic: NINDSPROJECT SUMMARY/ABSTRACT Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder after Alzheimer’s disease with prevalence estimated at 0.3% in the general population and at 1% in individuals over age 60 (Getz and Levin, 2017). In addition to the cardinal motor features associated with this illness, individuals with PD also experience cognitive decline. While estimates ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Therapy and Prophylaxis for Genital Tract Infection
SBC: THERAPYX, INC. Topic: NIAIDABSTRACT GneX12 is a patented therapeutic vaccine in development specifically for women with Neisseria gonorrhoeae (gonorrhea) infection. It is a novel formulation of recombinant human interleukin-12 (IL-12) encapsulated in biodegradable sustained release micro-particles. It is meant to be given in conjunction with standard of care antibiotics to turn infections into live vaccines that generate pr ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea
SBC: AIMMAX THERAPEUTICS INC Topic: NIAIDPROJECT SUMMARY / ABSTRACT The CDC has identified Neisseria gonorrhoeae as a pathogen of the highest threat level (“Urgent Threat”) to the US public health. Currently there is only a single recommended agent remaining on the CDC treatment guidelines, an intramuscular injection of the extended spectrum cephalosporin, ceftriaxone. However, in the past decade, reports of resistance to ceftriaxone ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Commercializing CivaSheet for Pancreatic Cancer Patients
SBC: CIVATECH ONCOLOGY INC Topic: NCICivaTech Oncology’s mission is to provide improved radiation therapy directly to diseased tissues while sparing healthy tissues. With NIH/NCI SBIR support, the Company has eliminated local recurrence of disease in pancreatic cancer patients – a huge success. Pancreatic cancer is predicted to soon become the most commonly diagnosed cancer in the US and there are no significant, impactful therap ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Rapid and robust assay for measurement of in vivo activity of chromatin-interacting proteins
SBC: Epicypher, Inc. Topic: NIAIDPROJECT SUMMARYThe activity of chromatin-associating proteins (CAPs) is fundamental to regulation of gene expression. Elucidating CAP activity is central to understanding the regulatory mechanisms that drive cell biology, both in the context of health and disease, and to guide development of novel therapeutics. However, this work is not straightforward, as CAP activity is regulated by multiple fac ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
SBC: Inhalon Biopharma Inc Topic: NIAIDTitle: GMP manufacturing and IND Filing of IN-002, a potent inhaled “muco-trapping” antibody therapy for Respiratory Syncytial Virus Project Summary (30 line limit) Respiratory Syncytial Virus (RSV) is the leading cause of viral hospitalization and death in infants and young children and is also a major cause of respiratory illness in immune compromised adults and the elderly. Unfortunately, t ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-959
SBC: T3D Therapeutics, Inc. Topic: NIAT3D-959 is a new chemical entity, orally delivered, small molecule, dual nuclear receptor agonist aimed at improving dysfunctional brain glucose energy and lipid metabolism in Alzheimer’s disease (AD), it is non- amyloid/non-tau-directed. Metabolic homeostasis, inherently altered in AD, leads to protein misfolding resulting in plaque formation, tangle formation and inflammation. Exploratory huma ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health